DK0719140T3 - Anvendelse af thiazolidindioner til forebyggelse eller forsinkelse af indtræden af NIDDM - Google Patents

Anvendelse af thiazolidindioner til forebyggelse eller forsinkelse af indtræden af NIDDM

Info

Publication number
DK0719140T3
DK0719140T3 DK94929204T DK94929204T DK0719140T3 DK 0719140 T3 DK0719140 T3 DK 0719140T3 DK 94929204 T DK94929204 T DK 94929204T DK 94929204 T DK94929204 T DK 94929204T DK 0719140 T3 DK0719140 T3 DK 0719140T3
Authority
DK
Denmark
Prior art keywords
niddm
onset
delay
prevent
thiazolidinediones
Prior art date
Application number
DK94929204T
Other languages
English (en)
Inventor
Dean Lockwood
Jerrold Olefsky
Tammy Antonucci
Rebecca Norris
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08293899 external-priority patent/US5478852C1/en
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of DK0719140T3 publication Critical patent/DK0719140T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94929204T 1993-09-15 1994-09-14 Anvendelse af thiazolidindioner til forebyggelse eller forsinkelse af indtræden af NIDDM DK0719140T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12225193A 1993-09-15 1993-09-15
US08293899 US5478852C1 (en) 1993-09-15 1994-08-23 Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
PCT/US1994/010389 WO1995007694A1 (en) 1993-09-15 1994-09-14 Use of thiazolidinediones to prevent or delay onset of niddm

Publications (1)

Publication Number Publication Date
DK0719140T3 true DK0719140T3 (da) 2008-03-03

Family

ID=26820333

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94929204T DK0719140T3 (da) 1993-09-15 1994-09-14 Anvendelse af thiazolidindioner til forebyggelse eller forsinkelse af indtræden af NIDDM

Country Status (16)

Country Link
EP (2) EP0719140B1 (da)
JP (3) JP3081245B2 (da)
CN (3) CN1103590C (da)
AT (1) ATE376829T1 (da)
AU (3) AU679572B2 (da)
CA (1) CA2171827C (da)
CZ (1) CZ283339B6 (da)
DK (1) DK0719140T3 (da)
ES (1) ES2296288T3 (da)
FI (1) FI961213A (da)
HK (1) HK1011925A1 (da)
HU (1) HU228260B1 (da)
NO (3) NO310097B1 (da)
NZ (1) NZ274346A (da)
RU (1) RU2195282C2 (da)
WO (1) WO1995007694A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5874454A (en) * 1993-09-15 1999-02-23 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
WO1997040017A2 (en) * 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
ATE399545T1 (de) * 1996-11-08 2008-07-15 Nippon Chemiphar Co Mittel zur verringerung der eigeweidefette
AU754479B2 (en) * 1997-05-15 2002-11-14 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
HUP9902721A2 (hu) 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US6699866B2 (en) 2001-04-17 2004-03-02 Sepracor Inc. Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
US6531461B1 (en) * 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
EP1588708A4 (en) * 2003-01-29 2006-03-01 Takeda Pharmaceutical METHOD FOR PRODUCING COATED PREPARATION
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
CN1761465B (zh) * 2003-01-29 2010-10-13 武田药品工业株式会社 制备被覆制剂的方法
FR2858321B1 (fr) * 2003-07-28 2006-01-20 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
CA2646207C (en) * 2006-03-16 2016-01-19 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
JP2826379B2 (ja) * 1990-01-22 1998-11-18 三共株式会社 チアゾリジン誘導体を有効成分とする肥満性高血圧症治療剤
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
WO1993000343A1 (en) * 1991-06-25 1993-01-07 Pfizer Inc. Thiazolidinedione hypoglycemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2688220A1 (fr) * 1992-03-06 1993-09-10 Adir Nouveaux derives de thiazolidine-2,4-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
EP0719140A1 (en) 1996-07-03
JPH09502727A (ja) 1997-03-18
NO310097B1 (no) 2001-05-21
RU2195282C2 (ru) 2002-12-27
NO314748B1 (no) 2003-05-19
FI961213A0 (fi) 1996-03-15
NO2963A (no) 1996-05-14
NO2964A (no) 1996-05-14
NO20002963D0 (no) 2000-06-09
AU706947B2 (en) 1999-07-01
ES2296288T3 (es) 2008-04-16
NO961041L (no) 1996-05-14
CA2171827A1 (en) 1995-03-23
EP1714652A2 (en) 2006-10-25
AU1770997A (en) 1997-05-29
AU7835194A (en) 1995-04-03
AU1771097A (en) 1997-05-29
CN1134669A (zh) 1996-10-30
FI961213A (fi) 1996-05-14
EP0719140B1 (en) 2007-10-31
EP1714652A3 (en) 2007-01-17
HU9600653D0 (en) 1996-05-28
JP2000273043A (ja) 2000-10-03
CN1202823C (zh) 2005-05-25
HUT75874A (en) 1997-05-28
NO314747B1 (no) 2003-05-19
CN1202821C (zh) 2005-05-25
JP3081245B2 (ja) 2000-08-28
CZ79396A3 (en) 1996-10-16
NO20002964D0 (no) 2000-06-09
EP0719140A4 (en) 2001-08-16
JP2000239167A (ja) 2000-09-05
NO961041D0 (no) 1996-03-14
AU679572B2 (en) 1997-07-03
ATE376829T1 (de) 2007-11-15
NZ274346A (en) 1997-06-24
WO1995007694A1 (en) 1995-03-23
CN1103590C (zh) 2003-03-26
HU228260B1 (en) 2013-02-28
CA2171827C (en) 2004-06-29
CN1387848A (zh) 2003-01-01
CN1387849A (zh) 2003-01-01
CZ283339B6 (cs) 1998-03-18
HK1011925A1 (en) 1999-07-23

Similar Documents

Publication Publication Date Title
DK0719140T3 (da) Anvendelse af thiazolidindioner til forebyggelse eller forsinkelse af indtræden af NIDDM
PL348773A1 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
NZ336689A (en) A method of treating polycystic ovary syndrome with thiazolidinedione derivatives
BR8902380A (pt) Aparelho para uso na operacao de uma ferramenta de poco de furo descendente tendo um elemento sensivel a pressao,e processo para controlar tal operacao
AU4714393A (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
HU9203837D0 (en) Method for producing oxa-dione and thiazolidin-dione compounds reducing sugar and cholesterol levels of blood
HU9400350D0 (en) Retard peptides
AU4815890A (en) Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus
AU8107694A (en) Use of substituted thiazolidine derivatives in the treatment of raised intraocular pressure
NO934836D0 (no) Fremgangsmaate for fremstilling og anvendelse som medikament eller diagnostikum av 2,4-substituerte 5-(N-substituerte-sulfamoyl)-benzoylgu anidiner, og medikamenter som inneholder disse
AU1405595A (en) Use of thalidomide for the treatment of non-insulin dependent diabetes mellitus
MY102454A (en) Adhesive sheets for sticking wafers thereto
EP0353418A3 (de) Verfahren und Schaumstoff-Körper zur Abschottung von Hohlkörpern
AU1065788A (en) Dissolved composition of (benzo-1,2,4-thiadiazine)-1,1-dioxide
CS38584A2 (en) Zpusob pripravy 5 (2 alkoxyfenyl) thiazolidindionu
EP0362742A3 (de) Verfahren zum getrennten Auftragen eines flüssigen Zweikomponenten-Leimsystems auf die Oberfläche von Holzteilen
ATE163940T1 (de) Flüssige stärke mit hohem festkörpergehalt hergestellt durch diskontinuierliches kochen
IL70880A (en) N-methyl-s-methyl-n'(2-(2-dimethylaminomethylthiazol-4-ylmethylthio)ethyl)-isothiourea,its preparation and use in the preparation of nizatidine
AU552937B2 (en) Spiro-chroman-imidazolidine
ES2038799T3 (es) Derivados de 3-ciano-4-fenil-pirrol.
DE58906207D1 (de) Substituierte 2-Aminothiazole.
IT8848548A0 (it) Procedimento per il post-trattamento di substrati tinti, stampati o foulardati
EP0320271A3 (en) Dimethylsulfoxide and analogues as anti-retroviral agents
IE830412L (en) Antidiabetic compositions
JPS5552005A (en) Reflection type polarizing plate